Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

Emily J. Tsai, David A. Kass

Research output: Contribution to journalReview articlepeer-review

244 Scopus citations


Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)216-238
Number of pages23
JournalPharmacology and Therapeutics
Issue number3
StatePublished - Jun 2009


  • Cardiovascular disease
  • Natriuretic peptide receptor
  • PKG
  • Phosphodiesterases
  • Soluble guanylyl cyclase
  • cGMP

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics'. Together they form a unique fingerprint.

Cite this